Fetal Fentanyl Syndrome: Unveiling a New Syndrome Linked to Fentanyl Use During Pregnancy
Dr. Karen Gripp, MD, Chief of the Division of Medical Genetics at Nemours Children’s Health in Wilmington, has been at…
Boston Company Uses AI Technology to Speed Up Diagnosis Times
March 13, 2018
PATIENT WORTHY
“A Boston biotech company called FNDA has collaborated with research organizations to utilize artificial intelligence, AI, to aid drug development and disease diagnosis, reports FierceBiotech. They are currently looking for partners to join the Genome Collaborative, a group of organizations working towards the same mission. They hope with the technology they will be able to help millions of patients globally who are undiagnosed.”
The article highlights how FDNA, a Boston-based company, leverages advanced AI technologies to expedite the diagnosis of rare genetic disorders. By utilizing its cutting-edge Face2Gene platform, FDNA analyzes facial features and phenotypic data to quickly and accurately identify genetic conditions. This AI-driven approach significantly reduces diagnosis times, providing quicker access to appropriate treatments for patients. FDNA’s innovative use of AI technologies exemplifies the potential for artificial intelligence to transform medical diagnostics and improve patient outcomes in the field of rare diseases.
Related articles
Continue reading
Interview with Dr. Giulia Pascolini: Unravelling the Genetic Underpinnings of Dermatological Anomalies
Dr Giulia Pascolini, an esteemed Italian M.D. and Ph.D., is currently responsible for the Genetic Counselling Service of the Istituto…
Spanish Coffin Siris Syndrome Association: Fighting for Health and Recognition
Founded in 2017, the Spanish Coffin Siris Syndrome Association is an organization dedicated to supporting families affected by this rare…